Source comparison
Best Tesamorelin Dosage Visceral Fat Reduction 2026: Protocol Comparison
Standard FDA-Approved 2mg SC Evening (within 2h of bedtime) 15–20% mean reduction +6–9 mg/dL fasting glucose Patients with baseline HbA1c <6.0%, no insulin resistance Gold standard. Maximizes VAT loss with acceptable metabolic trade-off Modified Start (Conserv
This comparison does not assign a generated winner or score.
- Standard FDA-Approved
- 2mg SC
- Evening (within 2h of bedtime)
- 15–20% mean reduction
- +6–9 mg/dL fasting glucose
- Patients with baseline HbA1c <6.0%, no insulin resistance
- Gold standard. Maximizes VAT loss with acceptable metabolic trade-off
- Modified Start (Conservative)
- 1.4mg SC for 8 weeks, then 2mg
- Evening
- 12–16% mean reduction
- +3–5 mg/dL fasting glucose
- Patients with HbA1c 6.0–6.4% or fasting glucose 100–125 mg/dL
- Safer ramp for prediabetics; slightly slower VAT reduction but better glucose tolerance
- High-Dose (Off-Label)
- 3mg SC
- 17–22% mean reduction
- +12–18 mg/dL fasting glucose
- Rarely justified. Only in research settings with tight glucose monitoring
- Higher risk of hyperglycemia and edema without proportional benefit; not recommended for clinical use
- Alternate-Day Dosing
- 2mg SC every other day
- Evening on dosing days
- 8–11% mean reduction
- Minimal glucose impact
- Poor adherence patients or those intolerant of daily injections
- Significantly reduced efficacy. VAT reduction less than 50% of daily dosing; not evidence-based